Treatment of canine visceral leishmaniasis by the vaccine Leish-111f + MPL-SE

Vaccine

Volumn 28, Issue 19, 2010, Pages 3333-3340

  Trigo, Joelma ^a   Abbehusen, Melissa ^a   Netto, Eduardo M ^b   Nakatani, Maria ^b   Pedral Sampaio, Geraldo ^b   de Jesus, Robson Silva ^b   Goto, Yasuyuki ^c   Guderian, Jeffrey ^c   Howard, Randall F ^c   Reed, Steven G ^c  

^a Canil Avançado em Monte Gordo de Pesquisa em Leishmanioses   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

Adjuvant; Dog; Immunotherapy; Leishmania infantum; Vaccine; Visceral leishmaniasis

Indexed keywords

LEISHMANIA VACCINE; MEGLUMINE ANTIMONATE; PHOSPHORYL LIPID A;

ANIMAL EXPERIMENT; ARTICLE; BRAZIL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; BRAZIL; DOGS; IMMUNOTHERAPY; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; TREATMENT OUTCOME;

EID: 77950627826     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.02.089     Document Type: Article

References (40)

1. Lukes J., Mauricio I.L., Schonian G., Dujardin J.C., Soteriadou K., Dedet J.P., et al. Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy. Proc Natl Acad Sci USA 104 22 (2007) 9375-9380
2. Chappuis F., Sundar S., Hailu A., Ghalib H., Rijal S., Peeling R.W., et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?. Nat Rev Microbiol 5 11 (2007) 873-882
3. Moreno J., and Alvar J. Canine leishmaniasis: epidemiological risk and the experimental model. Trends Parasitol 18 9 (2002) 399-405
4. Dantas-Torres F. The role of dogs as reservoirs of Leishmania parasites, with emphasis on Leishmania (Leishmania) infantum and Leishmania (Viannia) braziliensis. Vet Parasitol 149 3-4 (2007) 139-146
5. Dantas-Torres F. Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine. Vet Parasitol 141 1-2 (2006) 1-8
6. Gramiccia M., and Gradoni L. The current status of zoonotic leishmaniases and approaches to disease control. Int J Parasitol 35 11-12 (2005) 1169-1180
7. Gavgani A.S., Hodjati M.H., Mohite H., and Davies C.R. Effect of insecticide-impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: a matched-cluster randomised trial. Lancet 360 9330 (2002) 374-379
8. Reithinger R., and Davies C.R. Canine leishmaniasis: novel strategies for control. Trends Parasitol 18 7 (2002) 289-290
9. Dietze R., Barros G.B., Teixeira L., Harris J., Michelson K., Falqueto A., et al. Effect of eliminating seropositive canines on the transmission of visceral leishmaniasis in Brazil. Clin Infect Dis 25 5 (1997) 1240-1242
10. Cunha S., Freire M., Eulalio C., Critosvao J., Netto E., Johnson Jr. W.D., et al. Visceral leishmaniasis in a new ecological niche near a major metropolitan area of Brazil. Trans R Soc Trop Med Hyg 89 2 (1995) 155-158
11. Silva E.S., Gontijo C.M., Pacheco R.S., Fiuza V.O., and Brazil R.P. Visceral leishmaniasis in the metropolitan region of Belo Horizonte, State of Minas Gerais, Brazil. Mem Inst Oswaldo Cruz 96 3 (2001) 285-291
12. Baneth G., and Shaw S.E. Chemotherapy of canine leishmaniasis. Vet Parasitol 106 4 (2002) 315-324
13. Tesh R.B. Control of zoonotic visceral leishmaniasis: is it time to change strategies?. Am J Trop Med Hyg 52 3 (1995) 287-292
14. Alvar J., Molina R., San Andres M., Tesouro M., Nieto J., Vitutia M., et al. Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy. Ann Trop Med Parasitol 88 4 (1994) 371-378
15. Oliva G., Foglia Manzillo V., and Pagano A. Canine leishmaniasis: evolution of the chemotherapeutic protocols. Parasitologia 46 1-2 (2004) 231-234
16. Riera C., Valladares J.E., Gallego M., Aisa M.J., Castillejo S., Fisa R., et al. Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate. Vet Parasitol 84 1-2 (1999) 33-47
17. Reithinger R., Coleman P.G., Alexander B., Vieira E.P., Assis G., and Davies C.R. Are insecticide-impregnated dog collars a feasible alternative to dog culling as a strategy for controlling canine visceral leishmaniasis in Brazil?. Int J Parasitol 34 1 (2004) 55-62
18. Foglia Manzillo V., Oliva G., Pagano A., Manna L., Maroli M., and Gradoni L. Deltamethrin-impregnated collars for the control of canine leishmaniasis: evaluation of the protective effect and influence on the clinical outcome of Leishmania infection in kennelled stray dogs. Vet Parasitol 142 1-2 (2006) 142-145
19. Saraiva E.M., de Figueiredo Barbosa A., Santos F.N., Borja-Cabrera G.P., Nico D., Souza L.O., et al. The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine. Vaccine 24 13 (2006) 2423-2431
20. Lemesre J.L., Holzmuller P., Goncalves R.B., Bourdoiseau G., Hugnet C., Cavaleyra M., et al. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine 25 21 (2007) 4223-4234
21. +) T cells. Infect Immun 75 9 (2007) 4648-4654
22. Coler R.N., Skeiky Y.A., Bernards K., Greeson K., Carter D., Cornellison C.D., et al. Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun 70 8 (2002) 4215-4225
23. Velez I.D., Gilchrist K., Martinez S., Ramirez-Pineda J.R., Ashman J.A., Alves F.P., et al. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 28 2 (2009) 329-337
24. Reed S.G., Coler R.N., and Campos-Neto A. Development of a leishmaniasis vaccine: the importance of MPL. Expert Rev Vaccines 2 2 (2003) 239-252
25. Gradoni L., Foglia Manzillo V., Pagano A., Piantedosi D., De Luna R., Gramiccia M., et al. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine 23 45 (2005) 5245-5251
26. Miret J., Nascimento E., Sampaio W., Franca J.C., Fujiwara R.T., Vale A., et al. Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis. Vaccine 26 12 (2008) 1585-1594
27. Badaro R., Benson D., Eulalio M.C., Freire M., Cunha S., Netto E.M., et al. rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis 173 3 (1996) 758-761
28. Porrozzi R., Santos da Costa M.V., Teva A., Falqueto A., Ferreira A.L., dos Santos C.D., et al. Comparative evaluation of enzyme-linked immunosorbent assays based on crude and recombinant leishmanial antigens for serodiagnosis of symptomatic and asymptomatic Leishmania infantum visceral infections in dogs. Clin Vaccine Immunol 14 5 (2007) 544-548
29. Goto Y., Howard R.F., Bhatia A., Trigo J., Nakatani M., Netto E.M., et al. Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs. Vet Parasitol 160 3-4 (2009) 215-220
30. Pozio E., Gradoni L., Bettini S., and Gramiccia M. Leishmaniasis in Tuscany (Italy): VI. Canine leishmaniasis in the focus of Monte Argentario (Grosseto). Acta Trop 38 4 (1981) 383-393
31. Ikeda-Garcia F.A., Lopes R.S., Marques F.J., de Lima V.M., Morinishi C.K., Bonello F.L., et al. Clinical and parasitological evaluation of dogs naturally infected by Leishmania (Leishmania) chagasi submitted to treatment with meglumine antimoniate. Vet Parasitol 143 3-4 (2007) 254-259
32. Denerolle P., and Bourdoiseau G. Combination allopurinol and antimony treatment versus antimony alone and allopurinol alone in the treatment of canine leishmaniasis (96 cases). J Vet Intern Med 13 5 (1999) 413-415
33. Rojas R., Valderrama L., Valderrama M., Varona M.X., Ouellette M., and Saravia N.G. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis 193 10 (2006) 1375-1383
34. Barbieri C.L. Immunology of canine leishmaniasis. Parasite Immunol 28 7 (2006) 329-337
35. Pinelli E., Gonzalo R.M., Boog C.J., Rutten V.P., Gebhard D., del Real G., et al. Leishmania infantum-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner. Eur J Immunol 25 6 (1995) 1594-1600
36. Pinelli E., Killick-Kendrick R., Wagenaar J., Bernadina W., del Real G., and Ruitenberg J. Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum. Infect Immun 62 1 (1994) 229-235
37. Lage R.S., Oliveira G.C., Busek S.U., Guerra L.L., Giunchetti R.C., Correa-Oliveira R., et al. Analysis of the cytokine profile in spleen cells from dogs naturally infected by Leishmania chagasi. Vet Immunol Immunopathol 115 1-2 (2007) 135-145
38. Arevalo I., Ward B., Miller R., Meng T.C., Najar E., Alvarez E., et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 33 11 (2001) 1847-1851
39. Buates S., and Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis 179 6 (1999) 1485-1494
40. Walker P.S., Scharton-Kersten T., Krieg A.M., Love-Homan L., Rowton E.D., Udey M.C., et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci USA 96 12 (1999) 6970-6975